← Leaderboards
Ravi Kumar Anchoori
Up Therapeutics, Inc.
$2,755,931
Attributed
$2,755,931
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2021–24$2M$1.5M$1M$500K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,755,931 · 3
By mechanism
R44$2,047,415 · 1
R41$708,516 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Medical”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- Lynn Briscoe · Leidos Biomedical Research, Inc.$96,732,394
- Klaus Romero · Critical Path Institute$88,602,036
Research focus
MedicalResistanceSolid NeoplasmUbiquitinMulticatalytic Endopeptidase ComplexApoptosisProteinsSafetyStressTumorPharmaceutical PreparationsToxic EffectLeadNovel TherapeuticsProteasome InhibitorBortezomibReceptorLegal PatentPharmaceutical ChemistryIn Vitro ActivityInhibitorIn VivoMultiple MyelomaNeutropenia
Grant awards (5)
Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients$1,178,998
R44 · FY2024 · CA · contact PI
Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients$868,417
R44 · FY2023 · CA · contact PI
Development of small molecule RPN13 inhibitors for Treatment of Glioblastoma$400,000
R41 · FY2022 · CA · contact PI
Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer$55,000
R41 · FY2022 · CA · contact PI
Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer$253,516
R41 · FY2021 · CA · contact PI